Long Ideas - With a gain of more than 27% over the past year, Celgene (NASDAQ:CELG) serves as a solid example of the balance between stability and growth … Continue Reading
Read NowLong Ideas - Shares of BioMarin Pharmaceuticals (NASDAQ:BMRN) have risen roughly 40% in 2012, driven by solid Phase III data for BMRN’s lead investigational product GALNS, a treatment … Continue Reading
Read NowLong Ideas - Raptor Pharmaceutical (NASDAQ:RPTP) is developing treatments for rare diseases and has a compelling pipeline positioned to take advantage of unmet medical needs. The company has … Continue Reading
Read NowLong Ideas - Shares of ViroPharma (NASDAQ:VPHM) have been pressured in 2012 (falling over 17% as of December 26), as generic competition for one of its drugs has … Continue Reading
Read NowLong Ideas - For biotechnology investors, a biotechnology company’s “pivot” period, the time frame when it transitions from a development-stage company to a solidly profitable company can often … Continue Reading
Read NowLong Ideas - Orexigen Therapeutics (OREX) will be the last of three leading weight-loss drug developers to enter the large potential market for new obesity treatments, and biotech … Continue Reading
Read NowLong Ideas - It’s not easy to do, but buying when there’s blood in the streets is a way many have scored big on Wall Street. Take our … Continue Reading
Read Now